AVEO Pharmaceuticals (STU:VPA1) Accounts Payable & Accrued Expense : €25.45 Mil (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Accounts Payable & Accrued Expense?

AVEO Pharmaceuticals's quarterly accounts payable & accrued expense increased from Mar. 2022 (€15.28 Mil) to Jun. 2022 (€20.88 Mil) and increased from Jun. 2022 (€20.88 Mil) to Sep. 2022 (€25.45 Mil).

AVEO Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2019 (€7.38 Mil) to Dec. 2020 (€7.65 Mil) and increased from Dec. 2020 (€7.65 Mil) to Dec. 2021 (€11.66 Mil).

AVEO Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for AVEO Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Accounts Payable & Accrued Expense Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

10.05

10.03

7.38

7.65

11.66

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															14.27	11.66	15.28	20.88	25.45

AVEO Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines